PMID- 30278813
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 33
IP  - 2
DP  - 2020 Apr
TI  - Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
PG  - 213-216
LID - 10.1177/0897190018802129 [doi]
AB  - In the area of multiple myeloma (MM) therapy, proteasome inhibitors (PI) have 
      emerged with promising responses both in the first- and second-line setting. 
      Carfilzomib (CFZ) is a second-generation, selective PI approved in 2012 for the 
      treatment of relapsed/refractory multiple myeloma (RRMM) in patients who received 
      2 prior therapies or have evidence of disease progression within 60 days of 
      completion of last therapy. Its safety profile reported adverse events (AEs) 
      ranging from drug-related AEs (nausea and vomiting), hematologic AEs (neutropenia 
      and thrombocytopenia), and nonhematologic AEs (electrolyte imbalances). As CFZ 
      use is gaining popularity, various hematological, renal, cardiovascular, 
      pulmonary, and neurological toxicities have been reported. We are presenting this 
      case to describe a rare occurrence of tumor lysis syndrome (TLS) with the use of 
      this novel targeted therapy.
FAU - Sandy, El Bitar
AU  - Sandy EB
AUID- ORCID: 0000-0002-2625-9171
AD  - Department of Internal Medicine, Northwell Health Staten Island University 
      Hospital, Staten Island, NY, USA.
FAU - Weerasinghe, Chanudi
AU  - Weerasinghe C
AD  - Department of Hematology and Oncology, Northwell Health Staten Island University 
      Hospital, Staten Island, NY, USA.
FAU - Terjanian, Terenig
AU  - Terjanian T
AD  - Department of Hematology and Oncology, Northwell Health Staten Island University 
      Hospital, Staten Island, NY, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20181002
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oligopeptides)
RN  - 0 (Proteasome Inhibitors)
RN  - 72X6E3J5AR (carfilzomib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Humans
MH  - Male
MH  - Multiple Myeloma/*drug therapy
MH  - Nausea/chemically induced
MH  - Neutropenia/chemically induced
MH  - Oligopeptides/*adverse effects
MH  - Proteasome Inhibitors/*adverse effects
MH  - Thrombocytopenia/chemically induced
MH  - Tumor Lysis Syndrome/*etiology
MH  - Vomiting/chemically induced
MH  - Water-Electrolyte Balance/drug effects
OTO - NOTNLM
OT  - adverse events
OT  - carfilzomib
OT  - multiple myeloma
OT  - proteasome inhibitor
OT  - tumor lysis syndrome
EDAT- 2018/10/04 06:00
MHDA- 2021/01/05 06:00
CRDT- 2018/10/04 06:00
PHST- 2018/10/04 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2018/10/04 06:00 [entrez]
AID - 10.1177/0897190018802129 [doi]
PST - ppublish
SO  - J Pharm Pract. 2020 Apr;33(2):213-216. doi: 10.1177/0897190018802129. Epub 2018 
      Oct 2.